This Stock Under $2 Could Go to $20 (And STILL Be a SCREAMING BUY)

From Oxford Club | Ad

Analysts predict earnings will soar more than 320% this year...Possibly as much as 500%!

Discover the last opportunity that could still rocket skyward in THIS market.

Click Here to Discover Details on the Shocking Less Than $2 Stock.

>>>

CARA Insider Trading (Cara Therapeutics)

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 6.20%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $943,215.14

Cara Therapeutics Insider Trading History Chart

Cara Therapeutics Share Price & Price History

^$8.39

▼ -0.01 (-0.12%)

As of 05/16/2022 03:22 PM ET

Days: 30 | 90 | 365

Investor Alert: Argentina Loaded With "White Gold" Opportunity

From Investing Trends | Ad

Experts expect the global lithium market to grow by 500% due to the explosion of electric vehicles and green energy. And one small-cap company just snagged a large lithium deposit in a renowned South American location.

Read about this once-in-a-lifetime opportunity

Cara Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/4/2022	Christopher Posner	CEO	Sell	2,006	$12.67	$25,416.02	201,031
4/1/2022	Frederique Ph.D. Menzaghi	SVP	Sell	1,784	$11.91	$21,247.44	169,781
4/1/2022	Scott Terrillion	Insider	Sell	1,642	$11.91	$19,556.22	74,893
3/3/2022	Scott Terrillion	Insider	Sell	1,787	$11.38	$20,336.06
3/3/2022	Thomas Charles Reilly	CFO	Sell	2,044	$11.38	$23,260.72
2/25/2022	Scott Terrillion	Insider	Sell	1,972	$10.29	$20,291.88
11/12/2021	Jeffrey L. Ives	Director	Sell	8,180	$16.04	$131,207.20
11/1/2021	Joana Goncalves	Insider	Sell	1,000	$17.15	$17,150.00
10/27/2021	Joana Goncalves	Insider	Sell	1,000	$15.00	$15,000.00
9/7/2021	Derek T. Chalmers	CEO	Sell	20,000	$15.47	$309,400.00	991,405
8/30/2021	Derek T Chalmers	CEO	Sell	8,440	$14.20	$119,848.00	1,011,405
8/30/2021	Frederique Ph.D. Menzaghi	SVP	Sell	3,847	$14.20	$54,627.40	141,072
8/30/2021	Scott Terrillion	Insider	Sell	1,759	$14.20	$24,977.80	47,900
8/30/2021	Thomas Charles Reilly	CFO	Sell	1,982	$14.20	$28,144.40
6/7/2021	Martin Vogelbaum	Director	Sell	8,640	$13.05	$112,752.00	28,800
4/21/2021	Joana Goncalves	Insider	Sell	3,000	$27.63	$82,890.00	43,610
3/22/2021	Joana Goncalves	Insider	Sell	3,000	$19.65	$58,950.00	30,610
3/5/2021	Derek T Chalmers	CEO	Sell	3,103	$17.98	$55,791.94	953,614
3/5/2021	Frederique Ph.D. Menzaghi	SVP	Sell	3,358	$17.98	$60,376.84	122,677
3/5/2021	Scott Terrillion	Insider	Sell	3,090	$17.98	$55,558.20	54,432
2/25/2021	Derek T Chalmers	CEO	Sell	11,729	$19.33	$226,721.57	955,343
2/25/2021	Frederique Ph.D. Menzaghi	SVP	Sell	5,003	$19.33	$96,707.99	117,680
2/25/2021	Scott Terrillion	Insider	Sell	4,004	$19.33	$77,397.32	48,436
1/21/2021	Joana Goncalves	Insider	Sell	2,000	$20.12	$40,240.00	28,075
12/30/2020	Derek T Chalmers	CEO	Sell	6,078	$15.30	$92,993.40	936,593
12/30/2020	Frederique Ph.D. Menzaghi	SVP	Sell	2,812	$15.30	$43,023.60	109,680
12/30/2020	Scott Terrillion	Insider	Sell	1,946	$15.30	$29,773.80	42,436
12/28/2020	Derek T Chalmers	CEO	Sell	5,000	$16.00	$80,000.00	947,671
12/21/2020	Joana Goncalves	Insider	Sell	2,000	$15.00	$30,000.00	27,373
12/16/2020	Derek T Chalmers	CEO	Sell	5,000	$14.95	$74,750.00	928,921
12/10/2020	Derek T Chalmers	CEO	Sell	7,500	$15.29	$114,675.00	933,921
11/23/2020	Joana Goncalves	Insider	Sell	2,000	$15.31	$30,620.00	29,373
11/19/2020	Christopher Posner	Director	Sell	2,000	$15.82	$31,640.00	11,200
11/17/2020	Derek T Chalmers	CEO	Sell	11,799	$16.00	$188,784.00	941,421
11/17/2020	Martin Vogelbaum	Director	Sell	6,000	$16.09	$96,540.00	14,400
11/10/2020	Joana Goncalves	Insider	Sell	2,000	$15.00	$30,000.00	31,373
10/20/2020	Joana Goncalves	Insider	Sell	2,000	$15.00	$30,000.00	33,373
9/3/2020	Derek T Chalmers	CEO	Sell	3,201	$16.00	$51,216.00	953,220
7/1/2020	Derek T Chalmers	CEO	Sell	5,000	$17.11	$85,550.00	961,421
6/12/2020	Joana Goncalves	Insider	Sell	10,627	$15.05	$159,936.35	46,000
6/3/2020	Derek T Chalmers	CEO	Sell	4,300	$16.01	$68,843.00	970,721
6/1/2020	Derek T Chalmers	CEO	Sell	700	$16.00	$11,200.00	970,721
6/1/2020	Jeffrey L. Ives	Director	Sell	1,000	$16.00	$16,000.00	7,000
5/22/2020	Derek T Chalmers	CEO	Sell	371	$16.00	$5,936.00	975,292
5/20/2020	Derek T Chalmers	CEO	Sell	1,200	$16.00	$19,200.00	975,292
5/12/2020	Derek T Chalmers	CEO	Sell	4,929	$16.00	$78,864.00	976,492
5/12/2020	Jeffrey L. Ives	Director	Sell	2,500	$16.00	$40,000.00	8,500
4/21/2020	Derek T Chalmers	CEO	Sell	6,348	$15.56	$98,774.88	987,769
4/21/2020	Frederique Ph.D. Menzaghi	SVP	Sell	12,894	$15.58	$200,888.52	117,386
4/21/2020	Jeffrey L. Ives	Director	Sell	2,500	$16.00	$40,000.00	8,500
4/21/2020	Scott Terrillion	Insider	Sell	2,721	$15.56	$42,338.76	41,103
3/4/2020	Jeffrey L. Ives	Director	Sell	2,500	$16.00	$40,000.00	8,500
1/2/2020	Derek T Chalmers	CEO	Sell	10,000	$16.05	$160,500.00	917,769
1/2/2020	Jeffrey L. Ives	Director	Sell	2,500	$16.13	$40,325.00	8,500
12/4/2019	Derek T Chalmers	CEO	Sell	10,699	$17.05	$182,417.95	918,468
12/4/2019	Mani Mohindru	CFO	Sell	4,755	$17.05	$81,072.75	22,196
12/4/2019	Scott Terrillion	Insider	Sell	3,980	$17.05	$67,859.00	20,749
12/2/2019	Derek T Chalmers	CEO	Sell	10,000	$25.79	$257,900.00	918,468
12/2/2019	Jeffrey L. Ives	Director	Sell	2,500	$25.83	$64,575.00	8,500
11/1/2019	Derek T Chalmers	CEO	Sell	5,000	$20.79	$103,950.00	928,468
11/1/2019	Jeffrey L. Ives	Director	Sell	2,500	$20.68	$51,700.00	8,500
10/25/2019	Frederique Ph.D. Menzaghi	SVP	Sell	4,000	$19.91	$79,640.00	63,886
10/18/2019	Frederique Ph.D. Menzaghi	SVP	Sell	4,000	$19.33	$77,320.00	67,886
10/11/2019	Frederique Ph.D. Menzaghi	SVP	Sell	4,000	$18.70	$74,800.00	71,886
10/4/2019	Frederique Ph.D. Menzaghi	SVP	Sell	4,000	$19.19	$76,760.00	75,886
10/1/2019	Derek T Chalmers	CEO	Sell	10,000	$18.28	$182,800.00	933,468
10/1/2019	Jeffrey L. Ives	Director	Sell	2,500	$18.21	$45,525.00	8,500
9/3/2019	Derek T Chalmers	CEO	Sell	5,000	$23.26	$116,300.00	943,468
9/3/2019	Frederique Ph.D. Menzaghi	SVP	Sell	20,000	$22.92	$458,400.00	79,886
9/3/2019	Jeffrey L. Ives	Director	Sell	2,500	$23.31	$58,275.00	8,500
8/1/2019	Derek T Chalmers	CEO	Sell	10,000	$23.27	$232,700.00	948,468
8/1/2019	Frederique Ph.D. Menzaghi	SVP	Sell	20,000	$23.24	$464,800.00	99,886
8/1/2019	Jeffrey L. Ives	Director	Sell	2,500	$23.24	$58,100.00	8,500
7/17/2019	Frederique Ph.D. Menzaghi	Insider	Sell	8,996	$27.50	$247,390.00	119,886
7/15/2019	Mani Mohindru	CFO	Sell	37,431	$25.00	$935,775.00	51,294
7/1/2019	Frederique Ph.D. Menzaghi	Insider	Sell	20,000	$21.90	$438,000.00	128,882
7/1/2019	Jeffrey L. Ives	Director	Sell	2,500	$21.75	$54,375.00	8,500
5/29/2019	Derek T Chalmers	CEO	Sell	5,528	$21.42	$118,409.76	963,996
5/29/2019	Frederique Ph.D. Menzaghi	Insider	Sell	11,397	$21.19	$241,502.43	160,279
5/29/2019	Mani Mohindru	CFO	Sell	2,496	$21.39	$53,389.44	16,359

Warning: The Last Value Play Gone After August?

From Oxford Club | Ad

In this market...There's ONE STOCK (priced at just under $2) that could be $20 and STILL be a bargain. It brought in more income – including equity sales - in the last 12 months than Disney, Square or Tesla.

But a key announcement in August could send this stock rocketing skyward.

Get the Details Now.

SEC Filings (Institutional Ownership Changes) for Cara Therapeutics (NASDAQ:CARA)

56.56% of Cara Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Cara Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
5/16/2022	State Street Corp	1,680,599	$20.42M	0.0%	+12.3%	3.136%
5/16/2022	Disciplined Growth Investors Inc. MN	1,694,350	$20.59M	0.4%	+2.3%	3.162%
5/16/2022	Vident Investment Advisory LLC	107,982	$1.31M	0.0%	+75.9%	0.201%
5/16/2022	Invesco Ltd.	276,655	$3.36M	0.0%	-5.8%	0.516%
5/16/2022	UBS Group AG	15,781	$0.19M	0.0%	-57.5%	0.029%
5/13/2022	Renaissance Technologies LLC	159,150	$1.93M	0.0%	-55.9%	0.297%
5/13/2022	Chescapmanager LLC	1,175,392	$14.28M	1.9%	-9.9%	2.193%
5/13/2022	Northern Trust Corp	551,223	$6.70M	0.0%	-3.2%	1.029%
5/13/2022	Charles Schwab Investment Management Inc.	310,718	$3.78M	0.0%	-16.6%	0.580%
5/13/2022	Penserra Capital Management LLC	189,074	$2.30M	0.1%	-0.8%	0.353%
5/13/2022	Federated Hermes Inc.	6,009	$73K	0.0%	+27.7%	0.011%
5/13/2022	American International Group Inc.	25,256	$0.31M	0.0%	-5.9%	0.047%
5/13/2022	Vanguard Group Inc.	3,244,377	$39.42M	0.0%	+7.0%	6.054%
5/13/2022	Dimensional Fund Advisors LP	792,191	$9.63M	0.0%	+49.1%	1.478%
5/12/2022	BlackRock Inc.	7,187,124	$87.32M	0.0%	-0.2%	13.411%
5/12/2022	Commonwealth of Pennsylvania Public School Empls Retrmt SYS	36,096	$0.44M	0.0%	+13.1%	0.067%
5/12/2022	Metropolitan Life Insurance Co NY	2,988	$36K	0.0%	-75.4%	0.006%
5/12/2022	MetLife Investment Management LLC	27,279	$0.33M	0.0%	+49.8%	0.051%
5/12/2022	Martingale Asset Management L P	58,733	$0.71M	0.0%	+14.1%	0.110%
5/12/2022	Natixis Advisors L.P.	37,972	$0.46M	0.0%	+101.2%	0.071%
5/12/2022	Citigroup Inc.	86,370	$1.05M	0.0%	+5.7%	0.161%
5/12/2022	Connor Clark & Lunn Investment Management Ltd.	115,732	$1.41M	0.0%	-16.1%	0.216%
5/12/2022	Cambridge Investment Research Advisors Inc.	20,132	$0.25M	0.0%	+14.1%	0.038%
5/11/2022	Bank of New York Mellon Corp	439,181	$5.34M	0.0%	+0.7%	0.820%
5/11/2022	State of Tennessee Treasury Department	15,514	$0.19M	0.0%	-44.4%	0.029%
5/11/2022	Jupiter Asset Management Ltd.	193,472	$2.35M	0.0%	+613.3%	0.361%
5/11/2022	JPMorgan Chase & Co.	299,217	$3.64M	0.0%	-10.6%	0.558%
5/11/2022	GSA Capital Partners LLP	12,564	$0.15M	0.0%	N/A	0.023%
5/10/2022	ProShare Advisors LLC	15,321	$0.19M	0.0%	-17.4%	0.029%
5/10/2022	Meeder Asset Management Inc.	2,302	$28K	0.0%	N/A	0.004%
5/10/2022	Fox Run Management L.L.C.	10,938	$0.13M	0.1%	N/A	0.020%
5/9/2022	Principal Financial Group Inc.	365,982	$4.45M	0.0%	-11.5%	0.683%
5/9/2022	Swiss National Bank	101,100	$1.23M	0.0%	+14.9%	0.189%
5/9/2022	Qube Research & Technologies Ltd	17,018	$0.21M	0.0%	N/A	0.032%
5/6/2022	IndexIQ Advisors LLC	33,798	$0.41M	0.0%	N/A	0.063%
5/5/2022	Royce & Associates LP	111,592	$1.36M	0.0%	+744.0%	0.208%
5/5/2022	Russell Investments Group Ltd.	32,946	$0.40M	0.0%	-14.1%	0.061%
5/5/2022	Pinnacle Associates Ltd.	740,106	$8.99M	0.2%	+93.5%	1.381%
5/4/2022	Envestnet Asset Management Inc.	21,043	$0.26M	0.0%	N/A	0.039%
4/29/2022	SG Americas Securities LLC	75,333	$0.92M	0.0%	-17.5%	0.141%
4/28/2022	Davy Global Fund Management Ltd	126,507	$1.54M	0.3%	-27.7%	0.236%
4/27/2022	Comerica Bank	35,284	$0.46M	0.0%	-3.0%	0.066%
4/27/2022	New York State Teachers Retirement System	47,244	$0.57M	0.0%	+64.4%	0.088%
4/26/2022	First Citizens Bank & Trust Co.	20,208	$0.25M	0.0%	N/A	0.038%
4/21/2022	Strs Ohio	48,800	$0.59M	0.0%	-25.9%	0.091%
4/21/2022	Zurcher Kantonalbank Zurich Cantonalbank	5,886	$72K	0.0%	-42.3%	0.011%
4/21/2022	Virginia Retirement Systems ET AL	38,400	$0.47M	0.0%	-30.1%	0.072%
4/18/2022	Rothschild Investment Corp IL	51,400	$0.63M	0.0%	+5.1%	0.096%
4/14/2022	IBM Retirement Fund	26,509	$0.32M	0.0%	-34.2%	0.050%
4/14/2022	State of Alaska Department of Revenue	29,130	$0.35M	0.0%	-2.7%	0.054%
4/13/2022	Baldwin Brothers LLC MA	18,327	$0.22M	0.0%	+41.0%	0.034%
4/7/2022	Woodstock Corp	35,522	$0.43M	0.1%	+17.8%	0.066%
2/23/2022	Barclays PLC	80,673	$0.98M	0.0%	+59.1%	0.151%
2/23/2022	BlackRock Inc.	7,199,126	$87.68M	0.0%	+1.3%	13.467%
2/19/2022	Vident Investment Advisory LLC	61,392	$0.75M	0.0%	+4.1%	0.115%
2/19/2022	Wells Fargo & Company MN	132,793	$1.62M	0.0%	-29.1%	0.248%
2/18/2022	Comerica Bank	36,379	$0.43M	0.0%	-4.9%	0.068%
2/17/2022	Goldman Sachs Group Inc.	126,047	$1.54M	0.0%	-58.9%	0.236%
2/16/2022	Deutsche Bank AG	27,277	$0.33M	0.0%	+6.7%	0.051%
2/16/2022	California State Teachers Retirement System	57,834	$0.70M	0.0%	+1.9%	0.108%
2/16/2022	Parametric Portfolio Associates LLC	124,448	$1.52M	0.0%	-34.2%	0.233%
2/16/2022	State of Tennessee Treasury Department	27,883	$0.34M	0.0%	+40.3%	0.052%
2/15/2022	Penserra Capital Management LLC	190,676	$2.32M	0.0%	-1.5%	0.357%
2/15/2022	Metropolitan Life Insurance Co NY	12,146	$0.15M	0.0%	-8.9%	0.023%
2/15/2022	Stifel Financial Corp	59,239	$0.72M	0.0%	-32.5%	0.111%
2/15/2022	Kingdon Capital Management L.L.C.	883,000	$10.76M	1.2%	+23.4%	1.652%
2/15/2022	Legal & General Group Plc	101,138	$1.23M	0.0%	+3.8%	0.189%
2/15/2022	Cubist Systematic Strategies LLC	109,085	$1.33M	0.0%	+481.7%	0.204%
2/15/2022	Disciplined Growth Investors Inc. MN	1,656,861	$20.18M	0.4%	-0.7%	3.099%
2/14/2022	PDT Partners LLC	109,617	$1.34M	0.1%	+4.7%	0.205%
2/14/2022	Virtus ETF Advisers LLC	13,699	$0.17M	0.1%	-7.4%	0.026%
2/14/2022	Squarepoint Ops LLC	14,449	$0.18M	0.0%	+11.1%	0.027%
2/14/2022	Point72 Asset Management L.P.	358,300	$4.36M	0.0%	N/A	0.670%
2/14/2022	Guggenheim Capital LLC	12,324	$0.15M	0.0%	N/A	0.023%
2/14/2022	Alliancebernstein L.P.	45,222	$0.55M	0.0%	-17.7%	0.085%
2/14/2022	Credit Suisse AG	49,625	$0.61M	0.0%	+10.6%	0.093%
2/14/2022	State Street Corp	1,496,500	$18.23M	0.0%	-0.5%	2.799%
2/14/2022	LPL Financial LLC	159,706	$1.95M	0.0%	-4.5%	0.299%
2/14/2022	Goldman Sachs Group Inc.	126,047	$1.54M	0.0%	-58.9%	0.236%
2/14/2022	Nuveen Asset Management LLC	328,037	$3.86M	0.0%	-3.1%	0.614%
2/14/2022	Soleus Capital Management L.P.	427,200	$5.20M	0.5%	N/A	0.799%
2/14/2022	Barclays PLC	80,673	$0.98M	0.0%	+59.1%	0.151%
2/14/2022	Invesco Ltd.	293,696	$3.58M	0.0%	+37.2%	0.549%
2/11/2022	Geode Capital Management LLC	841,028	$10.24M	0.0%	+0.5%	1.573%
2/11/2022	Renaissance Technologies LLC	360,950	$4.40M	0.0%	N/A	0.675%
2/11/2022	Charles Schwab Investment Management Inc.	372,481	$4.54M	0.0%	+2.2%	0.697%
2/10/2022	Rhumbline Advisers	129,889	$1.58M	0.0%	-0.8%	0.243%
2/10/2022	JPMorgan Chase & Co.	334,594	$4.08M	0.0%	+190.6%	0.626%
2/10/2022	Rafferty Asset Management LLC	14,187	$0.17M	0.0%	N/A	0.027%
2/10/2022	Citigroup Inc.	81,716	$1M	0.0%	+85.3%	0.153%
2/10/2022	WINTON GROUP Ltd	20,316	$0.25M	0.0%	-50.2%	0.038%
2/10/2022	B. Riley Wealth Management Inc.	32,770	$0.40M	0.0%	-4.4%	0.061%
2/10/2022	Connor Clark & Lunn Investment Management Ltd.	137,895	$1.68M	0.0%	-6.6%	0.258%
2/9/2022	Principal Financial Group Inc.	413,618	$5.04M	0.0%	+17.2%	0.774%
2/9/2022	BNP Paribas Arbitrage SA	36,320	$0.44M	0.0%	-34.6%	0.068%
2/9/2022	Dimensional Fund Advisors LP	531,350	$6.47M	0.0%	+50.1%	0.994%
2/9/2022	Geneos Wealth Management Inc.	2,060	$25K	0.0%	-33.4%	0.004%
2/8/2022	Bank of America Corp DE	90,289	$1.10M	0.0%	+26.3%	0.169%
2/8/2022	ProShare Advisors LLC	18,555	$0.23M	0.0%	+6.1%	0.035%
2/8/2022	Northern Trust Corp	569,197	$6.93M	0.0%	-3.8%	1.065%

Data available starting January 2016

Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

Today's Range

Now: $8.39

$8.09

$8.53

50 Day Range

MA: $11.49

$7.45

$13.84

52 Week Range

Now: $8.39

$7.40

$18.93

Volume

22,545 shs

Average Volume

594,839 shs

Market Capitalization

$449.63 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.22

Who are the company insiders with the largest holdings of Cara Therapeutics?: Cara Therapeutics' top insider investors include:
Derek T Chalmers (CEO)
Derek T Chalmers (CEO)
Christopher Posner (CEO)
Frederique PhD Menzaghi (SVP)
Scott Terrillion (Insider)
Joana Goncalves (Insider)
Martin Vogelbaum (Director)
Christopher Posner (Director)
Jeffrey L Ives (Director)
Thomas Charles Reilly (CFO)
Learn More about top insider investors at Cara Therapeutics.
Who are the major institutional investors of Cara Therapeutics?: Cara Therapeutics' top institutional investors include:
BlackRock Inc. — 13.41%
Vanguard Group Inc. — 6.05%
Disciplined Growth Investors Inc. MN — 3.16%
State Street Corp — 3.14%
Chescapmanager LLC — 2.19%
Dimensional Fund Advisors LP — 1.48%
Learn More about top institutional investors of Cara Therapeutics stock.
Which institutional investors are selling Cara Therapeutics stock?: During the last quarter, CARA stock was sold by these institutional investors:
Renaissance Technologies LLC
Chescapmanager LLC
Charles Schwab Investment Management Inc.
Davy Global Fund Management Ltd
Principal Financial Group Inc.
JPMorgan Chase & Co.
Connor Clark & Lunn Investment Management Ltd.
UBS Group AG
During the previous year, company insiders that have sold Cara Therapeutics company stock include:
Derek T Chalmers (CEO)
Derek T Chalmers (CEO)
Christopher Posner (CEO)
Frederique PhD Menzaghi (SVP)
Scott Terrillion (Insider)
Joana Goncalves (Insider)
Martin Vogelbaum (Director)
Christopher Posner (Director)
Jeffrey L Ives (Director)
Learn More investors selling Cara Therapeutics stock.
Which institutional investors are buying Cara Therapeutics stock?: During the previous quarter, CARA stock was purchased by institutional investors including:
Pinnacle Associates Ltd.
Dimensional Fund Advisors LP
Vanguard Group Inc.
State Street Corp
Jupiter Asset Management Ltd.
Royce & Associates LP
Vident Investment Advisory LLC
Disciplined Growth Investors Inc. MN

The Safest Option in Trades!

From Tradewins | Ad

If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.

And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!

Click here now!